Navigation Links
New Clinical Study Data Show the GlycoMark® Test Helps Confirm Compliance and Appropriate Response to SGLT-2 Inhibitors

GlycoMark, Inc. announced a new study “GlycoMark 1,5-Anhydroglucitol Values in Patients Taking SGLT-2 Inhibitors” presented at the American Diabetes Association (ADA) Scientific Sessions 2019 involving the GlycoMark test being used for patients with Type 2 diabetes that are being treated with an SGLT-2 inhibitor. SGLT-2 inhibitors are used to lower glucose levels in patients with diabetes by preventing glucose reabsorption by the kidneys and triggering glycosuria.

The GlycoMark test, an FDA-cleared and CE marked blood test used to monitor glycemic control in patients with diabetes, is sensitive and specific to detecting high blood glucose levels and glucose variability during the prior 1 to 2 weeks. A low GlycoMark result (generally less than 10 µg/mL) is abnormal and suggests glucose levels have exceeded dangerously high limits, including postprandial glucose variability, which can be missed in up to 40% of patients with a “good” A1C.(1) A previous study in patients taking an SGLT-2 inhibitor by Balis, et al reported extremely low GlycoMark test results that suggested drug interference and test inaccuracy, thereby negating utility in patients taking an SGLT-2 inhibitor. However, as stated in the GlycoMark test package insert, the low GlycoMark values associated with SGLT-2 inhibitor is caused by glycosuria, i.e. the effect of the drug, and is not interfering with the test itself.

In the study presented this week, clinical investigators from Aveon Health, Scottsdale, AZ, conducted a review of their patients treated with an SGLT-2 inhibitor from January 2015 to December 2018 and their corresponding GlycoMark test results, with the hypothesis that GlycoMark test results in patients taking SGLT-2 inhibitors would be extremely low due to persistent glycosuria, which may be useful for assessing patient compliance with and confirming the SGLT-2 inhibitor effect. Of the 240 patients being treated with an SGLT-2 inhibitor, 92% had a GlycoMark test result that was on the extremely low end of abnormal (less than or equal to µg/mL), and the average GlycoMark result was 1.2 µg/mL. “We have long suspected that SGLT-2 inhibitor use is associated with extremely low GlycoMark results, even lower than typically seen for moderately controlled patients with persistent hyperglycemia. We hypothesized that the extremely low GlycoMark results were not an indicator of very poor glycemic control but were rather indicating compliance with the medication as prescribed and achieving the desired effect, which is elimination of glucose in urine. These data support this hypothesis,” said Sam Fereidouni, MD, MHSA, a Family Physician and Medical Director at Aveon Health, lead investigator on the study. Using GlycoMark test results, investigators also identified 52 non-compliant patients that had an average GlycoMark result of 6.4 µg/mL.

Dr. Fereidouni, who has been using the GlycoMark test for over 8 years in his practice and who has exceeded national and private payor benchmarks aimed at reducing patient outcomes, encourages clinicians to include the GlycoMark test in their workup of patients with diabetes for its unique ability to detect glycemic variability not evident with A1C, fructosamine, or glycated albumin - tests that all report a glucose average. “GlycoMark results in addition to A1C provide a more complete assessment of glycemic control. By including the GlycoMark test, patients with glycemic control issues can be properly selected for continuous glucose monitoring, counseling, or other diabetes treatment modifications.”

“The study data support the sensitivity of the GlycoMark test to glycosuria, which is associated with hyperglycemia and hyperglycemic excursions, and may have utility in diabetes patients taking SGLT-2 inhibitors,” said Jeff Dahlen, PhD, VP Clinical Affairs at GlycoMark and co-author on the study.

Subsequent to incorporating the GlycoMark test into clinical practice, Dr. Fereidouni became a paid clinical consultant of GlycoMark.

Reference: 1. Erlinger TP, Brancati FL. Diabetes Care. 2001 Oct;24(10):1734-8.

About the GlycoMark test

The GlycoMark test provides quantitative measurement of 1,5-anhydroglucitol (1,5-AG) in serum or plasma. The test is for professional use, and is indicated for the intermediate term monitoring of glycemic control in people with diabetes. The GlycoMark Test has not been FDA cleared for monitoring SGLT-2 inhibitor effect.

About GlycoMark, Inc.

GlycoMark, Inc., based in Manhattan, New York, is dedicated to improving the management and health of patients with diabetes. The company is a joint venture among Toyota Tsusho America, Inc. (New York, NY), Toyota Tsusho Corporation (Tokyo, Japan), and Nippon Kayaku Co., Ltd. (Tokyo, Japan), and is the exclusive supplier of the GlycoMark test in the U.S., Europe, Australia, the Asia-Pacific Region and the Middle East. The GlycoMark test is an FDA cleared non-fasting blood test that detects hyperglycemia and hyperglycemic excursions occurring in the prior 1 to 2 weeks. Since its discovery, the GlycoMark Test, a quantitative test for 1,5-Anhydroglucitol (1,5-AG), has been described in more than 1,300 scientific and medical publications and is shown to be independently associated with complications of diabetes. More information is available at
GlycoMark, Inc. is the exclusive licensee of the GlycoMark test, trademark and logo.

Read the full story at

Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved

Related medicine news :

1. Kidney Week 2013: New innovations in clinical science
2. Salar Joins Medical Informatics Experts to Judge AMIA’s First Ever Student Design Challenge: Reinventing Clinical Documentation
3. The DelRay Recovery Center Appoints Britt Bonner as the Director of Clinical Outreach
4. Clinical trial looks at impact of platelet-rich plasma therapy on tennis elbow
5. Nemours receives Dept. of Defense award to study physicians maintenance of optimal clinical program
6. Clinical trial finds concurrent therapy not necessary to achieve high pathological in breast cancer
7. Catalent’s Clinical Trial Supply Facility in Shanghai, China Opens for Business
8. Italian study examines clinical predictors of acute urinary symptoms after radiotherapy for prostate
9. Idol Lash: The Clinically Proven Eyelash Growth Enhancer Now Available in the Market With 1 Extra Bottle Offer
10. Paid Asthma Clinical Trial Now Enrolling at Achieve Clinical Research Near Birmingham, Alabama; Accepting M/F Patients with Asthma Age 12 - 75
11. Tinnitus Global Clinical Trials Review, H2, 2013
Post Your Comments:
(Date:10/10/2019)... ... October 10, 2019 , ... In attendance at this year’s ... hear the significant results of an independent study presented by researchers from the ... study poster entitled “The Acute Effects of Citrulline Malate and Bonded Arginine Silicate ...
(Date:10/8/2019)... ... 2019 , ... What unique insights can three former Surgeons General of the ... the nation? That question will be answered at ICAA 2019: Shaping the Future of ... event will take place October 10-12, 2019, at the Gaylord Palms Resort and Convention ...
(Date:10/8/2019)... ... October 08, 2019 , ... In Vitro Sciences (IVS), ... Fertility Care (AFC), an advanced reproductive services (RE) facility operating in the greater ... RE services to expectant families throughout Arizona and the greater Southwest. , This ...
(Date:10/8/2019)... ... , ... Cognosante has been awarded a contract to continue ... Referrals and Authorizations program. The new task order will allow Cognosante ... enterprise-wide system used by community care staff to generate referrals and authorizations for ...
(Date:10/8/2019)... ... October 08, 2019 , ... As ... samples, Meiqing Shi, associate professor with the University of Maryland Department of Veterinary ... published in Nature Communications, Shi and his lab have discovered a new pathway ...
Breaking Medicine News(10 mins):
(Date:10/19/2019)... ... ... It has long been the practice that training programs for elite and professional ... to deliver their best performance. But, how do you know when you’re there? Imagine ... physiology, then be able to alter that effect. , Thought Technology’s peak performance physiology ...
(Date:10/17/2019)... ... 17, 2019 , ... One of the most prominent features on a person is the ears. ... stick out too far from the skull. This can cause a great deal of embarrassment ... and reduce the appearance of their ears. In order to help patients get the change ...
(Date:10/15/2019)... Ala. (PRWEB) , ... October 14, 2019 , ... An ... in a wrongful death medical malpractice case that breaks records for Lee County. , ... pains, difficulty breathing, and cough. She had been there just two days earlier with ...
Breaking Medicine Technology: